This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2019.
Company Filing History:
2 out of 2,405 
Years Active: 2019
Title: The Innovative Contributions of Andrew Gibb
Introduction
Andrew Gibb is a notable inventor based in Hertfordshire, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target the muscarinic M1 receptor. His work is particularly relevant for the treatment of Alzheimer's disease and other cognitive disorders.
Latest Patents
Andrew Gibb holds a patent for a process for making M1 receptor positive allosteric modulators. This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts, and derivatives thereof. The compounds synthesized by the processes of this invention are useful for treating Alzheimer's disease and other diseases mediated by the muscarinic M1 receptor.
Career Highlights
Andrew Gibb is currently associated with Merck Sharp & Dohme Corp., where he continues to advance his research in pharmacology and medicinal chemistry. His work has the potential to impact the treatment of various cognitive impairments and disorders.
Collaborations
Andrew has collaborated with notable colleagues such as Qinghao Chen and Lushi Tan. Their combined expertise contributes to the innovative research being conducted in the field.
Conclusion
Andrew Gibb's contributions to the field of medicinal chemistry, particularly through his patent on M1 receptor modulators, highlight his role as an influential inventor. His work promises to advance treatments for Alzheimer's disease and other related disorders.